

27 Jun 2018 | Analysis

QUOTED. June 27, 2018. Joe Friedrich.

by

For Boston Scientific, there were various reasons it had two of its facilities appraised by CMMI Institute under a US FDA maturity model pilot program. The company's quality assurance director, Joe Friedrich, talks about one of those reasons here.

"First off, we really were drawn to this idea of using the maturity model and practice capabilities in lieu of just a compliance approach, to really understand specific areas that our site can work on to improve. [A CMMI appraisal] felt like it would be maybe a better way to help us identify areas of improvement that could have a true effect on patient outcomes, and potentially be good for our business." –Joe Friedrich, quality assurance director, Boston Scientific

- Find out more: [*Boston Scientific, Edwards Lifesciences, Baxter Used CMMI To Measure Their Manufacturing Capability. Here's What They Said About The Experience*](#)

[*Click here*](#) for a free trial of *Medtech Insight*